Toxicity and Survival After Intensity-Modulated Proton Therapy Versus Passive Scattering Proton Therapy for NSCLC.

[1]  Z. Liao,et al.  Proton therapy for locally advanced non-small cell lung cancer. , 2020, The British journal of radiology.

[2]  K. Forster,et al.  Long-Term Results of NRG Oncology RTOG 0617: Standard- Versus High-Dose Chemoradiotherapy With or Without Cetuximab for Unresectable Stage III Non-Small-Cell Lung Cancer. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Joe Y. Chang,et al.  Proton therapy for non-small cell lung cancer: the road ahead. , 2019, Translational lung cancer research.

[4]  Zhongxing Liao,et al.  Clinical outcomes after intensity-modulated proton therapy with concurrent chemotherapy for inoperable non-small cell lung cancer. , 2019, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[5]  R. Mohan,et al.  Validation of Effective Dose as a Better Predictor of Radiation Pneumonitis Risk Than Mean Lung Dose: Secondary Analysis of a Randomized Trial. , 2019, International journal of radiation oncology, biology, physics.

[6]  D. Planchard,et al.  Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC , 2018, The New England journal of medicine.

[7]  Radhe Mohan,et al.  Bayesian Adaptive Randomization Trial of Passive Scattering Proton Therapy and Intensity-Modulated Photon Radiotherapy for Locally Advanced Non-Small-Cell Lung Cancer. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Tarek Mekhail,et al.  Durvalumab after Chemoradiotherapy in Stage III Non–Small‐Cell Lung Cancer , 2017, The New England journal of medicine.

[9]  M. Socinski,et al.  Cardiac Toxicity After Radiotherapy for Stage III Non-Small-Cell Lung Cancer: Pooled Analysis of Dose-Escalation Trials Delivering 70 to 90 Gy. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Radhe Mohan,et al.  Proton therapy - Present and future. , 2017, Advanced drug delivery reviews.

[11]  J. Galvin,et al.  Impact of Intensity-Modulated Radiation Therapy Technique for Locally Advanced Non-Small-Cell Lung Cancer: A Secondary Analysis of the NRG Oncology RTOG 0617 Randomized Clinical Trial. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Joe Y. Chang,et al.  Long-term outcomes after proton therapy, with concurrent chemotherapy, for stage II-III inoperable non-small cell lung cancer. , 2015, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[13]  W. Curran,et al.  Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. , 2015, The Lancet. Oncology.

[14]  Heng Li,et al.  Clinical implementation of intensity modulated proton therapy for thoracic malignancies. , 2014, International journal of radiation oncology, biology, physics.

[15]  Heng Li,et al.  Evaluation and mitigation of the interplay effects of intensity modulated proton therapy for lung cancer in a clinical setting. , 2014, Practical radiation oncology.

[16]  Radhe Mohan,et al.  Robust optimization of intensity modulated proton therapy. , 2012, Medical physics.

[17]  Joe Y. Chang,et al.  Phase 2 study of high‐dose proton therapy with concurrent chemotherapy for unresectable stage III nonsmall cell lung cancer , 2011, Cancer.

[18]  Radhe Mohan,et al.  Influence of technologic advances on outcomes in patients with unresectable, locally advanced non-small-cell lung cancer receiving concomitant chemoradiotherapy. , 2010, International journal of radiation oncology, biology, physics.

[19]  Radhe Mohan,et al.  Significant reduction of normal tissue dose by proton radiotherapy compared with three-dimensional conformal or intensity-modulated radiation therapy in Stage I or Stage III non-small-cell lung cancer. , 2006, International journal of radiation oncology, biology, physics.